Personal essays and analysis on Ozempic, weight-loss drugs, and the culture they created. Published intermittently. Always cultural, never prescriptive. Subscribe to the monthly letter to get the next one in your inbox.
Not medical advice, a cultural conversation. Ozemback is not affiliated with any pharmaceutical company or healthcare provider.
The cultural shorthand started in late 2024. Patients report blunted cravings (for food, alcohol, shopping, gambling, even Instagram). The mechanism is real: GLP-1 receptors are densely expressed in reward circuits. Here is the honest cultural read on what is signal and what is anecdote.
Read the essay →The obesity trials are finished and the filing is set for 2027. The liver indication runs years behind, and tolerability is the open question.
Read more → Analysis · RegulationThe trials are finished and the filing is set for early 2027. The open question is whether the FDA reviews it as a biologic or as a drug.
Read more → Analysis · RegulationFiled on 18 December 2025, a decision expected in the last quarter of 2026, a launch planned for early 2027, and one head-to-head trial that went to tirzepatide.
Read more → Analysis · Market / AccessOne address for the prescription, four outside pharmacies that dispense, a cash price Lilly sets, and a refill clock that moves the higher strengths from $449 to $699.
Read more → Analysis · Regulation / PeptidesA draft promise not to enforce, for six peptides, specific salts and routes, and licensed pharmacies only. The law and the 503A list have not moved.
Read more → Analysis · Coverage / MedicareYes, since July 2026, through a $50 demonstration outside Part D that ends on 31 December 2027. Who qualifies, why vials are out, and what comes after.
Read more → Analysis · Legal / enforcementThe "FTC crackdown" is mostly an FDA story. A 1971 agreement, 55 FDA letters in 2026, the FTC’s NextMed and Hims cases, and the gap where research peptides sell.
Read more → Analysis · Market / supply chainThe label says where a vial was packed. FDA import alerts, a customs seizure of 5,000 parcels and 2026 import data say where the powder was made, and who inspected the plant.
Read more → Analysis · Legal / marketThe video call is rarely the legal problem. The molecule and the pharmacy are, and the DEA deadline of 31 December matters for testosterone, not BPC-157.
Read more → Essay · NewFor a century the equation had two terms: diet and exercise. Then a generation woke up and the sentence had a third. An essay on what that third sentence does to a culture.
Read more →